Vimarsana
Biggest News Aggregation in the World

Faraday Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Faraday Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Faraday Pharmaceuticals Today - Breaking & Trending Today

Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of 7.7% During the Study Period (2019-2032), Predicts DelveInsight - Vimarsana News

Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of 7.7% During the Study Period (2019-2032), Predicts DelveInsight

/PRNewswire/ -- DelveInsight's Acute Myocardial Infarction Market Insights report includes a comprehensive understanding of current treatment practices, acute...

Myocardial Infarction (MI) Market is Projected to Grow at a Minimal CAGR of 1.61% During the Study Period (2019-2032) - Vimarsana News

Myocardial Infarction (MI) Market is Projected to Grow at a Minimal CAGR of 1.61% During the Study Period (2019-2032)

/PRNewswire/ -- DelveInsight's MI Market Insights report includes a comprehensive understanding of current treatment practices, MI emerging drugs, market share...

Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders - Vimarsana News

Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders

/PRNewswire/ -- Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer...

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction - Vimarsana News

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI

Actimed Therapeutics secures significant new patent, extending IP coverage of its lead compound for use in key indication - Vimarsana News

Actimed Therapeutics secures significant new patent, extending IP coverage of its lead compound for use in key indication

Provides extended UK patent coverage relating to lead compound S-pindolol benzoate (ACM-001.1) to 2040. International patent application also filed in March 2021. LONDON, May 4, 2022 /PRNewswire/